ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY

被引：0
|
作者：
Hernandez, Alba [1 ]
Calera, Lourdes [1 ]
Alvarez, Maria [1 ]
Hernando, Jorge [1 ]
Torres, Irene [1 ]
Pajares, Isabel [1 ]
Madani, Julia [1 ]
Cebollero, Ana [1 ]
Anton-Torres, Antonio [1 ]
Artal, Angel [1 ]
机构：
[1] Hosp Univ Miguel Servet, Zaragoza, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
erlotinib; second line; wild-type EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.24-036
引用
收藏
页码：S1017 / S1017
页数：1
相关论文
共 50 条
  • [31] Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)
    Kayali, F.
    Janjua, M. A.
    Laber, D. A.
    Miller, D. M.
    Day, J. M.
    Kloecker, G. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] A phase II trial of second-line erlotinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC)
    Iyengar, Puneeth
    Kavanagh, Brian D.
    Smith, Irma
    Ahn, Chul
    Gerber, David E.
    Dowell, Johnathan
    Hughes, Randall S.
    Abdulrahman, Ramzi
    Camidge, D. Ross
    Gaspar, Laurie E.
    Doebele, Robert Charles
    Bunn, Paul A.
    Choy, Hak
    Timmerman, Robert D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Real-world efficacy of first-line therapy in wild-type non-small cell lung cancer (NSCLC) patients with brain metastases
    Kong, B.
    Wei, J.
    Smith, S.
    Chan, W. Y.
    Harden, S. V.
    Khou, V.
    Alexander, M.
    Brown, C.
    Itchins, M.
    Lee, J.
    Mersiades, A.
    Gray, L.
    Boyer, M.
    Pavlakis, N.
    Clarke, S.
    Jayamanne, D.
    Kao, S. C-H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1577 - S1578
  • [34] ERLOTINIB IS HIGHLY ACTIVE IN SELECTED PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING WILD TYPE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
    Marquez-Medina, Diego
    Gasol Cudos, Ariadna
    Taberner Bonastre, Ma Teresa
    Martin Marco, Antonio
    Gomez Falguera, Silvia
    Ortega Izquierdo, Eugenia
    Mangues Bofarul, Irene
    Salud Salvia, Antonieta
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S118 - S119
  • [35] Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
    Okano, Yoshio
    Ando, Masahiko
    Asami, Kazuhiro
    Fukuda, Masaaki
    Nakagawa, Hideyuki
    Ibata, Hidenori
    Kozuki, Toshiyuki
    Endo, Tateo
    Tamura, Atsuhisa
    Kamimura, Mitsuhiro
    Sakamoto, Kazuhiro
    Yoshimi, Michihiro
    Soejima, Yoshifumi
    Tomizawa, Yoshio
    Isa, Shunichi
    Takada, Minoru
    Saka, Hideo
    Kubo, Akihito
    Kawaguchi, Tomoya
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
    Li, Yang-Ling
    Hu, Xiu
    Li, Qing-Yu
    Wang, Fei
    Zhang, Bo
    Ding, Ke
    Tan, Bi-Qin
    Lin, Neng-Ming
    Zhang, Chong
    MOLECULAR MEDICINE REPORTS, 2018, 18 (04) : 3882 - 3890
  • [37] Gemcitabine as single agent second line treatment in patients with advanced wild-type EGFR, negative ALK non-small cell lung cancer: a retrospective study
    Rinaldi, S.
    Morgese, F.
    Torniai, M.
    Savini, A.
    Barbotti, F.
    Pirani, F.
    Leoni, G.
    Grohe, C.
    Newsom-Davis, T.
    Paolucci, V.
    Bower, M.
    Fiordoliva, I.
    Berardi, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [39] Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line
    Van der Steen, Nele
    Leonetti, Alessandro
    Keller, Kaylee
    Dekker, Henk
    Funel, Niccola
    Lardon, Filip
    Ruijtenbeek, Rob
    Tiseo, Marcello
    Rolfo, Christian
    Pauwels, Patrick
    Peters, Godefridus J.
    Giovannetti, Elisa
    BIOCHEMICAL PHARMACOLOGY, 2019, 166 : 128 - 138
  • [40] Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations
    Wheler, Jennifer J.
    Tsimberidou, Apostolia M.
    Falchook, Gerald S.
    Zinner, Ralph G.
    Hong, David S.
    Fok, Jansina Y.
    Fu, Siqing
    Piha-Paul, Sarina A.
    Naing, Aung
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (10) : 2167 - 2175
12345